Pediatric drug development a new investment area in China
Shi Yingzi · 05/19/2022
A drugmaker specializing in medicines for children raising nearly $15.7 million in April 2022 shows a shifting interest toward this area. Early-stage biotech companies also made up 18 of the 27 financing deals.
READ MORE

Latest Articles

Roche China Accelerator to aid nine local biotech startups; VerImmune, U-Synbio, Hansoh
Elise Mak · 2 days ago
A year after its launch in Shanghai, Roche China Accelerator said it has identified nine local innovative drugmakers to join efforts with the pharma giant. More news from VerImmune, U-Synbio, Hansoh, ACEA Pharma, CANSino, Bayer.
News
Hengrui launches Luzsana to bring drugs to North America, Europe and Japan; Meton Pharma, CTTQ, Junshi
Elise Mak · 3 days ago
Chinese pharma giant Hengrui Pharma has launched a new company named Luzsana Biotechnology to co-develop medicines and commercialize them in North America, Europe and Japan. More news from Meton Pharma, CTTQ, Junshi.
News
Pediatric drug development a new investment area in China
Shi Yingzi · 3 days ago
A drugmaker specializing in medicines for children raising nearly $15.7 million in April 2022 shows a shifting interest toward this area. Early-stage biotech companies also made up 18 of the 27 financing deals.
China Biotech Fundraising Tracker
Laekna Therapeutics raises $61 Million in series D financing; Senlang, CStone, Simcere
Elise Mak · 4 days ago
Laekna Therapeutics, which is developing an AKT kinase inhibitor afuresertib and a CYP17/CYP11B2 dual inhibitor, said it closed a $61 million Series D round to accelerate the clinical development of these two drug candidates. More news from Senlang, CStone, Simcere.
News
Luye Pharma's biotech arm Boan seeks IPO in Hong Kong; MingMed, Immune-Onc, Sinopharm
Elise Mak · 5 days ago
Shandong Boan Biotechnology, established in 2013 as a subsidiary of Luye Pharma Group, is seeking an IPO in Hong Kong with support from UBS and Essence International to keep advancing its biological drug candidates. More news from MingMed, Immune-Onc, Sinopharm.
News
Kelun licenses out a large molecule drug candidate to MSD in $1.4B+ deal; Starna, Junshi, Gracell
Elise Mak · 6 days ago
Sichuan Kelun Pharmaceutical revealed a deal with MSD worth over $1.4 billion to license out a large molecule drug candidate in oncology for development and commercialization outside Greater China. More news from Starna, Junshi, Gracell, MSD, Biohealthcare, Hengrui Pharma.
News
Pfizer leads April approvals in China with two JAK inhibitors
Danni Yin · 6 days ago
April 2022 saw a number of foreign and licensed drugs approved in China, with the majority of them in oncology and rheumatology.
China NMPA Approval Tracker
Innovo Therapeutics receives angel funding to develop targeted protein degradation therapies; Zhaoke, Hengrui
Elise Mak · 9 days ago
Innovo Therapeutics, established in June 2021 with funding from Chinese and U.S. investors, said it has received angel funding of nearly RMB100 million to expand its two targeted protein degradation platforms and advance multiple immuno-oncology programs. More news from Zhaoke, Hengrui.
News
Henlius taps Latin America for its biosimilars with Brazil's Eurofarma; Greatsun, Ascletis Pharma
Elise Mak · 10 days ago
Shanghai's Henlius Biotech has made a deal worth up to $50.5 million with Brazil's Eurofarma to produce and market three of its biosimilars. More news from Greatsun, Ascletis Pharma.
News
Chinese securities regulators lay out audit pathway for U.S. listings
Elise Mak · 10 days ago
China has laid out the pathway to resolve auditing disputes with the U.S. but some bottom lines are drawn, lawyer says
Feature
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement